Source: Virtual Congress 2020 – COPD and the impact of comorbidities
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Palli (Ridgefield, United States of America), C. Elliott (Eden Prairie, United States of America), B. Xie (Eden Prairie, United States of America), B. Chastek (Eden Prairie, United States of America), L. Bengston (Eden Prairie, United States of America). Late Breaking Abstract - Compare outcomes between COPD patients treated with Tiotropium/Olodaterol (TIO/OLO) and other fixed-dose LAMA/LABAs. 2469

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Compare outcomes between COPD patients treated with tiotropium/olodaterol (TIO/OLO) and umeclidium/vilanterol (UMEC/VI) Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity Year: 2020 Late Breaking Abstract - Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Late Breaking Abstract - The efficacy of roflumilast in the treatment of COPD(stage B). Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Late Breaking Abstract - Prolonged azithromycin maintenance treatment in patients with COPD, a follow-up of the COLUMBUS trial Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Late Breaking Abstract - IMPACT study — single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs — UK Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Late Breaking Abstract - Assessment of physical functioning and handling with Tiotropium/Olodaterol (T/O) in patients with COPD requiring long-acting dual bronchodilation in an Italian cohort of patients. Source: International Congress 2019 – COPD treatment: cohorts and real-world studies Year: 2019 Late Breaking Abstract - Effectiveness of Fluticasone furoate/vilanterol (FF/VI) compared to usual care (UC) in patients with asthma: The Salford Lung Study (SLS) Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Late Breaking Abstract - Determinants of disease control in patients with severe COPD. The CLAVE Study Source: International Congress 2019 – Clinical approach to asthma management Year: 2019 Late Breaking Abstract - Effectiveness and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) from a large Italian practice cohort Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Late Breaking Abstract - Comparison of clinical characteristics between severe adult asthmatics in Brazil(ProAR) and Europe(U-BIOPRED). Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Late Breaking Abstract - Relationship between clinical features and mortality in a cohort of COPD patients. Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD Year: 2021 Late Breaking Abstract: Novel detection of exacerbations of COPD with patient reported outcome (EXACT-PRO) and Blackberry (BB) Source: Annual Congress 2010 - Asthma and COPD: understanding through monitoring Year: 2010 Late Breaking Abstract - Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Late Breaking Abstract - Factors associated with health-status of COPD patients on Dry Powder Inhaler (DPI) maintenance therapy Source: Virtual Congress 2021 – Highlights for primary care in 2021 Year: 2021 Late Breaking Abstract - Tocilizumab in hospitalized patients with severe COVID-19: an open label, prospective study Source: Virtual Congress 2021 – Respiratory infections Year: 2021 Late Breaking Abstract - Early benefits in patient-reported outcomes (PROs) and physical activity (PA) in patients with severe eosinophilic asthma (SEA) treated with benralizumab: interim analysis of the imPROve Asthma study Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Late Breaking Abstract - Identification of patients with COPD who benefit from benralizumab Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough Year: 2019